Return on Retained Earnings (RORE) is an indicator of a company's growth potential, it shows how much a company earns by reinvesting its retained earnings, i.e. profits after dividend payments.
European Medical Solutions's 3-Year RORE % for the quarter that ended in Dec. 2025 was 157.47%.
The industry rank for European Medical Solutions's 3-Year RORE % or its related term are showing as below:
STU:AS00's 3-Year RORE % is ranked better than 97.83% of 1289
companies
in the Biotechnology industry
Industry Median: -11.44
vs STU:AS00: 157.47
European Medical Solutions (STU:AS00) 3-Year RORE % Explanation
Return on Retained Earnings (RORE) is important to investors because it reveals a company's efficiency and growth potential. A higher RORE indicates a higher return. A high RORE indicates that the company should reinvest profits into the business. A lower RORE suggests that the company should distribute profits to shareholders by paying out dividends, since those dollars aren't generating much additional growth for the company.
There are a several different ways to arrive at the Return on Retained Earnings. The simplest way to calculate it is by using published information on Earnings per Share (EPS) and Dividend per Share (DPS) over a selected period. Here, 3-year period is chosen.
Be Aware
Please keep in mind that the RORE is relative to the nature of the business and its competitors. If another company in the same sector is producing a lower return on retained earnings, it doesn’t necessarily mean it’s a bad investment. It may just suggest the company is older and no longer in a high growth stage. At such a stage in the business cycle, it would be expected to see a lower RORE and higher dividend payout.
European Medical Solutions 3-Year RORE % Related Terms
European Medical Solutions 3-Year RORE % Historical Data
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
STU:AS00 vs VRTX, REGN, ALNY: 3-Year RORE % Comparison
For the Biotechnology subindustry, European Medical Solutions's 3-Year RORE %, along with its competitors' market caps and 3-Year RORE % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
European Medical Solutions 3-Year RORE % vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, European Medical Solutions's 3-Year RORE % distribution charts can be found below:
* The bar in red indicates where European Medical Solutions's 3-Year RORE % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
In the calculation of 3-Year RORE %, the most recent and first period EPS (Diluted) is the trailing twelve months (TTM) data ended in Dec. 2025 and 3-year before.
European Medical Solutions (STU:AS00) has a 3-Year RORE % of 157.47 as of Dec. 2025. 3-Year RORE % shows how much a company earns by reinvesting its retained earnings in 3-year. View historical data on European Medical Solutions and its competitors. According to the industry distribution chart, European Medical Solutions ranks #28 out of 1289 companies in the Biotechnology industry, placing it in the top 2.2%.
Is European Medical Solutions' 3-Year RORE % too high?
European Medical Solutions' current 3-Year RORE % is 157.47. Based on the distribution chart, European Medical Solutions ranks #28 out of 1289 companies in the Biotechnology industry, which is in the top quartile — a strong position relative to peers. Overall, European Medical Solutions has a GF Score™ of 43/100, reflecting its overall financial health beyond just this single metric.
How does European Medical Solutions' 3-Year RORE % compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, European Medical Solutions ranks #28 out of 1289 companies for 3-Year RORE %. This places European Medical Solutions in the top 2% of its industry — outperforming the majority of peers. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good 3-Year RORE % for a Biotechnology company?
A good 3-Year RORE % depends on the Biotechnology industry context. However, 3-Year RORE % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high 3-Year RORE % mean?
A high 3-Year RORE % can signal that a stock is expensive relative to its fundamentals. 3-Year RORE % shows how much a company earns by reinvesting its retained earnings in 3-year. View historical data on European Medical Solutions and its competitors. European Medical Solutions's current 3-Year RORE % is 157.47. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is European Medical Solutions stock overvalued right now?
European Medical Solutions (STU:AS00) has a current 3-Year RORE % of 157.47. The stock's GF Value™ is €8.16, compared to a current price of €3.98 — trading 51.2% below its estimated fair value. The current 3-Year RORE % is 157.47. European Medical Solutions' overall GF Score™ is 43/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is 3-Year RORE % calculated?
3-Year RORE % is calculated from a company's financial statements. For European Medical Solutions (STU:AS00), the current 3-Year RORE % is 157.47 as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is European Medical Solutions (STU:AS00) Overvalued in 2026?
Based on GuruFocus' analysis, European Medical Solutions stock appears to be undervalued.
The current stock price of €3.98 is trading 51.2% below its estimated GF Value™ of €8.16.
Key valuation signals for STU:AS00:
3-Year RORE %: 157.47
GF Value™: €8.16 vs. price of €3.98 (51.2% below fair value)
No single metric tells the full story. See the STU:AS00 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
European Medical Solutions Formerly DMS Imaging SA is a clinical-stage biopharmaceutical company. The company is engaged in the development and future commercialization of a range of breakthrough immunotherapy products for the treatment of allergies, based on its ASIT+ technology platform. Its lead product is gp-ASIT+, a phase III trial for the treatment of grass pollen rhinitis. Its pipeline products consist of hdm-ASIT+ for the treatment of house dust mite asthma; and pnt-ASIT+ for the treatment of peanut allergy.
43GF Score
Get the complete analysis for STU:AS00
3-Year RORE % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
STU:AS00 has been successfully added to your 
